Hemophilia B Gene Therapy Market Size, Share, Analysis, Growth, 2032
Hemophilia B Gene Therapy Market By Patient Age Group (Geriatric, Adults, and Pediatric), By Disease Severity (Severe Hemophilia B, Moderate Hemophilia B, and Mild Hemophilia B), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032
Category: Healthcare Report Format : PDF
Pages: 225 Report Code: ZMR-9183
Published Date: Jan-2025 Status : Published
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 0.51 Billion | USD 3.43 Billion | 23.60% | 2023 |
Table Of Content
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Hemophilia B Gene Therapy Market, (2024 - 2032) (USD Billion )
- 2.2 Global Hemophilia B Gene Therapy Market : snapshot
- Chapter 3. Global Hemophilia B Gene Therapy Market - Industry Analysis
- 3.1 Hemophilia B Gene Therapy Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Growing number of patients with hemophilia B to drive market demand rate
- 3.3 Market Restraints
- 3.3.1. Lack of access to the treatment to limit the industry’s growth rate during the forecast period
- 3.4 Market Opportunities
- 3.4.1. Ongoing research and innovation in gene therapy for the blood clotting disorder will create expansion possibilities
- 3.5 Market Challenges
- 3.5.1. Side-effects associated with gene therapy to challenge market expansion
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Patient Age Group
- 3.7.2 Market attractiveness analysis By Disease Severity
- Chapter 4. Global Hemophilia B Gene Therapy Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Hemophilia B Gene Therapy Market: company market share, 2032
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Hemophilia B Gene Therapy Market - Patient Age Group Analysis
- 5.1 Global Hemophilia B Gene Therapy Market overview: By Patient Age Group
- 5.1.1 Global Hemophilia B Gene Therapy Market share, By Patient Age Group, 2032 and 2032
- 5.2 Geriatric
- 5.2.1 Global Hemophilia B Gene Therapy Market by Geriatric, 2024 - 2032 (USD Billion )
- 5.3 Adults
- 5.3.1 Global Hemophilia B Gene Therapy Market by Adults, 2024 - 2032 (USD Billion )
- 5.4 Pediatric
- 5.4.1 Global Hemophilia B Gene Therapy Market by Pediatric, 2024 - 2032 (USD Billion )
- 5.1 Global Hemophilia B Gene Therapy Market overview: By Patient Age Group
- Chapter 6. Global Hemophilia B Gene Therapy Market - Disease Severity Analysis
- 6.1 Global Hemophilia B Gene Therapy Market overview: By Disease Severity
- 6.1.1 Global Hemophilia B Gene Therapy Market share, By Disease Severity, 2032 and 2032
- 6.2 Severe Hemophilia B
- 6.2.1 Global Hemophilia B Gene Therapy Market by Severe Hemophilia B, 2024 - 2032 (USD Billion )
- 6.3 Moderate Hemophilia B
- 6.3.1 Global Hemophilia B Gene Therapy Market by Moderate Hemophilia B, 2024 - 2032 (USD Billion )
- 6.4 Mild Hemophilia B
- 6.4.1 Global Hemophilia B Gene Therapy Market by Mild Hemophilia B, 2024 - 2032 (USD Billion )
- 6.1 Global Hemophilia B Gene Therapy Market overview: By Disease Severity
- Chapter 7. Hemophilia B Gene Therapy Market - Regional Analysis
- 7.1 Global Hemophilia B Gene Therapy Market Regional Overview
- 7.2 Global Hemophilia B Gene Therapy Market Share, by Region, 2032 & 2032 (USD Billion )
- 7.3. North America
- 7.3.1 North America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.3.1.1 North America Hemophilia B Gene Therapy Market, by Country, 2024 - 2032 (USD Billion )
- 7.3.1 North America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4 North America Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032
- 7.4.1 North America Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032 (USD Billion )
- 7.5 North America Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032
- 7.5.1 North America Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032 (USD Billion )
- 7.4. Europe
- 7.4.2 Europe Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4.2.1 Europe Hemophilia B Gene Therapy Market, by Country, 2024 - 2032 (USD Billion )
- 7.4.2 Europe Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4 Europe Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032
- 7.4.1 Europe Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032 (USD Billion )
- 7.5 Europe Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032
- 7.5.1 Europe Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032 (USD Billion )
- 7.5. Asia Pacific
- 7.5.3 Asia Pacific Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.5.3.1 Asia Pacific Hemophilia B Gene Therapy Market, by Country, 2024 - 2032 (USD Billion )
- 7.5.3 Asia Pacific Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4 Asia Pacific Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032
- 7.4.1 Asia Pacific Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032 (USD Billion )
- 7.5 Asia Pacific Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032
- 7.5.1 Asia Pacific Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032 (USD Billion )
- 7.6. Latin America
- 7.6.4 Latin America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.6.4.1 Latin America Hemophilia B Gene Therapy Market, by Country, 2024 - 2032 (USD Billion )
- 7.6.4 Latin America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4 Latin America Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032
- 7.4.1 Latin America Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032 (USD Billion )
- 7.5 Latin America Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032
- 7.5.1 Latin America Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032 (USD Billion )
- 7.7. The Middle-East and Africa
- 7.7.5 The Middle-East and Africa Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.7.5.1 The Middle-East and Africa Hemophilia B Gene Therapy Market, by Country, 2024 - 2032 (USD Billion )
- 7.7.5 The Middle-East and Africa Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 7.4 The Middle-East and Africa Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032
- 7.4.1 The Middle-East and Africa Hemophilia B Gene Therapy Market, by Patient Age Group, 2024 - 2032 (USD Billion )
- 7.5 The Middle-East and Africa Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032
- 7.5.1 The Middle-East and Africa Hemophilia B Gene Therapy Market, by Disease Severity, 2024 - 2032 (USD Billion )
- Chapter 8. Company Profiles
- 8.1 Freeline Therapeutics
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 CSL Behring
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Alnylam Pharmaceuticals
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Dimension Therapeutics
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Bayer AG
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Pfizer Inc.
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 Sangamo Therapeutics
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Roche Holding AG
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 Spark Therapeutics
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 Genethon
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.11 uniQure N.V.
- 8.11.1 Overview
- 8.11.2 Financials
- 8.11.3 Product Portfolio
- 8.11.4 Business Strategy
- 8.11.5 Recent Developments
- 8.12 REGENXBIO Inc.
- 8.12.1 Overview
- 8.12.2 Financials
- 8.12.3 Product Portfolio
- 8.12.4 Business Strategy
- 8.12.5 Recent Developments
- 8.13 BioMarin Pharmaceutical Inc.
- 8.13.1 Overview
- 8.13.2 Financials
- 8.13.3 Product Portfolio
- 8.13.4 Business Strategy
- 8.13.5 Recent Developments
- 8.14 Novo Nordisk A/S
- 8.14.1 Overview
- 8.14.2 Financials
- 8.14.3 Product Portfolio
- 8.14.4 Business Strategy
- 8.14.5 Recent Developments
- 8.15 Shire plc (now part of Takeda Pharmaceutical Company)
- 8.15.1 Overview
- 8.15.2 Financials
- 8.15.3 Product Portfolio
- 8.15.4 Business Strategy
- 8.15.5 Recent Developments
- 8.16 and others.
- 8.16.1 Overview
- 8.16.2 Financials
- 8.16.3 Product Portfolio
- 8.16.4 Business Strategy
- 8.16.5 Recent Developments
- 8.1 Freeline Therapeutics
Table Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 4. Porter’s Five Forces Analysis
- 5. Global Hemophilia B Gene Therapy Market attractiveness, By Patient Age Group
- 6. Global Hemophilia B Gene Therapy Market attractiveness, By Disease Severity
- 7. Global Hemophilia B Gene Therapy Market share by Patient Age Group, 2024 and 2032 (USD Billion )
- 8. Global Hemophilia B Gene Therapy Market by Geriatric, 2024 - 2032 (USD Billion )
- 9. Global Hemophilia B Gene Therapy Market by Adults, 2024 - 2032 (USD Billion )
- 10. Global Hemophilia B Gene Therapy Market by Pediatric, 2024 - 2032 (USD Billion )
- 11. Global Hemophilia B Gene Therapy Market share by Disease Severity, 2024 and 2032 (USD Billion )
- 12. Global Hemophilia B Gene Therapy Market by Severe Hemophilia B, 2024 - 2032 (USD Billion )
- 13. Global Hemophilia B Gene Therapy Market by Moderate Hemophilia B, 2024 - 2032 (USD Billion )
- 14. Global Hemophilia B Gene Therapy Market by Mild Hemophilia B, 2024 - 2032 (USD Billion )
- 15. Global Hemophilia B Gene Therapy Market share, by Region, 2024 and 2032
- 16. North America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 17. Europe Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 18. Asia Pacific Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 19. Latin America Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
- 20. The Middle-East and Africa Hemophilia B Gene Therapy Market, 2024 - 2032 (USD Billion )
Table Of Tables
- 1. Global Hemophilia B Gene Therapy Market: Snapshot
- 2. Drivers of the Hemophilia B Gene Therapy Market: impact analysis
- 3. North America Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 4. North America Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 5. U.S. Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 6. U.S. Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 7. Canada Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 8. Canada Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 9. Europe Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 10. Europe Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 11. Germany Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 12. Germany Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 13. France Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 14. France Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 15. U.K. Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 16. U.K. Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 17. Italy Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 18. Italy Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 19. Spain Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 20. Spain Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 21. Rest of Europe Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 22. Rest of Europe Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 23. Asia Pacific Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 24. Asia Pacific Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 25. China Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 26. China Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 27. Japan Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 28. Japan Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 29. India Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 30. India Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 31. South Korea Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 32. South Korea Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 33. South-East Asia Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 34. South-East Asia Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 35. Rest of Asia Pacific Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 36. Rest of Asia Pacific Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 37. Latin America Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 38. Latin America Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 39. Brazil Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 40. Brazil Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 41. Mexico Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 42. Mexico Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 43. Rest of Latin America Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 44. Rest of Latin America Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 45. The Middle-East and Africa Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 46. The Middle-East and Africa Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 47. GCC Countries Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 48. GCC Countries Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 49. South Africa Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 50. South Africa Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
- 51. Rest of Middle-East Africa Hemophilia B Gene Therapy Market revenue, By Patient Age Group, 2024 - 2032 (USD Billion )
- 52. Rest of Middle-East Africa Hemophilia B Gene Therapy Market revenue, By Disease Severity, 2024 - 2032 (USD Billion )
Methodology
FrequentlyAsked Questions
Hemophilia B gene therapy is a one-time novel medical treatment used for treating patients with hemophilia B medical conditions.
The global hemophilia B gene therapy market is expected to grow due to the rising number of patients suffering from the medical condition.
According to study, the global hemophilia B gene therapy market size was worth around USD 0.51 billion in 2023 and is predicted to grow to around USD 3.43 billion by 2032.
The CAGR value of the hemophilia B gene therapy market is expected to be around 23.60% during 2024-2032.
The global hemophilia B gene therapy market is expected to be dominated by North America in the coming years.
The global hemophilia B gene therapy market is led by players like Freeline Therapeutics, CSL Behring, Alnylam Pharmaceuticals, Dimension Therapeutics, Bayer AG, Pfizer Inc., Sangamo Therapeutics, Roche Holding AG, Spark Therapeutics, Genethon, uniQure N.V., REGENXBIO Inc., BioMarin Pharmaceutical Inc., Novo Nordisk A/S and Shire plc (now part of Takeda Pharmaceutical Company).
The report explores crucial aspects of the hemophilia B gene therapy market, including a detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.
HappyClients
